ArticleBritish journal of cancer2026

Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer-comparing real-world outcomes in England to the MONARCH-2 trial.

Jack Anderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.